Health & Fitness
Mon, August 1, 2011Sun, July 31, 2011Fri, July 29, 2011Thu, July 28, 2011Wed, July 27, 2011Tue, July 26, 2011Mon, July 25, 2011Sat, July 23, 2011Fri, July 22, 2011Thu, July 21, 2011Wed, July 20, 2011Tue, July 19, 2011Mon, July 18, 2011Fri, July 15, 2011Thu, July 14, 2011Wed, July 13, 2011Tue, July 12, 2011Mon, July 11, 2011Sun, July 10, 2011Sat, July 9, 2011Fri, July 8, 2011Thu, July 7, 2011Wed, July 6, 2011PPD Comments on Recent Stock Market Developments
//health-fitness.news-articles.net/content/2011/ .. omments-on-recent-stock-market-developments.html
Published in Health and Fitness on Monday, July 18th 2011 at 12:15 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
WILMINGTON, N.C.--([ BUSINESS WIRE ])--Following recent stock market developments, PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors has asked management to review PPDa™s strategic plan and capital structure with a focus on unlocking value for shareholders.
"While the company generally has a policy of not commenting on speculation"
aWhile the company generally has a policy of not commenting on speculation,a said Fred Eshelman, executive chairman of PPD, awe want to assure our customers and employees that the company remains focused on executing its long-term business strategy.a Eshelman added, aWe are absolutely dedicated to performing for our customers and committed to executing the important research programs that they have entrusted to us.a
Eshelman continued, aWe are looking at our long-term plan and our capital structure to see if there are any actions, which might create value at this time. We are not engaged in any discussions around a combination with other clinical research providers. We remain laser-focused on executing our business and serving our customers with the quality and service they expect and deserve.a
About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit [ www.ppdi.com ].
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions relating to PPDa™s strategic plan and capital structure, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: economic conditions, R&D spending levels and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; overall global economic conditions; competition in the outsourcing industry; PPDa™s ability to win new business; the rate of conversion of backlog into revenue; loss, delay or modification of large contracts; higher-than-expected cancellation rates; actual operating performance; fluctuations in currency exchange rates; risks associated with and dependence on strategic relationships; our ability to implement and risks associated with stock repurchases; rapid technological advances that make our services less competitive; risks associated with acquisitions and investments, such as impairments and integration, including PPDa™s investment in Celtic Therapeutics; the ability to attract, integrate and retain key personnel, including a new CEO; our ability to control SG&A spending; risks associated with fixed price contracts and cost overruns; consolidation in the pharmaceutical and biotechnology industries; and risks that we may increase, reduce or discontinue our dividend policy.These and other PPD risk factors are set forth in more detail from time to time in our SEC filings, copies of which are available free of charge upon request from PPDa™s investor relations department.PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable securities laws.These forward-looking statements should not be relied upon as representing PPDa™s estimates or views as of any date subsequent to the date hereof.
